<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885946</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-254-20</org_study_id>
    <nct_id>NCT04885946</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection</brief_title>
  <acronym>EarlyFMT</acronym>
  <official_title>Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Hvas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovation Fund Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need&#xD;
      for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for&#xD;
      recurrent Clostridioides difficile infection (CDI), and is currently recommended for multiple&#xD;
      (three or more), recurrent CDI infections. The role of FMT earlier in the treatment hierarchy&#xD;
      of CDI remains to be determined.&#xD;
&#xD;
      In this randomized, double-blinded, placebo-controlled clinical trial, we compare FMT with&#xD;
      placebo following standard antibiotic treatment for first or second Clostridioides difficile&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel arm placebo-controlled clinical trial. We aim to include 84 adult patients&#xD;
      with their first or second episode of Clostridioides difficile (formerly Clostridium&#xD;
      difficile) infection. All patients receive vancomycin standard therapy. Patients are&#xD;
      randomised in a 1:1 ratio to two treatments with capsules that contain either FMT+FMT or&#xD;
      placebo+placebo. The primary outcome is absence of C difficile-associated disease 8 weeks&#xD;
      after randomisation. Patients who have fulminant disease where it is deemed unethical to give&#xD;
      placebo are offered open-label FMT. The primary outcome in patients with fulminant C&#xD;
      difficile infection is 8 weeks mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients are randomized to either vancomycin + 2 FMT or 2 placebo. An open-label arm exists for patients with fulminant CDI.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of CD-associated diarrhea (CDAD) week 8</measure>
    <time_frame>8 weeks following treatment</time_frame>
    <description>Measured as a combined clinical resolution or persistent diarrhea, but with negative CD test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality week 8</measure>
    <time_frame>8 weeks following treatment</time_frame>
    <description>In the open-label arm for patients who cannot be randomized due to ethical reasons, the primary outcome is mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of CD-associated diarrhea (CDAD) week 1</measure>
    <time_frame>1 week following treatment</time_frame>
    <description>Measured as a combined clinical resolution or persistent diarrhea, but with negative CD test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative CD toxin-test week 1</measure>
    <time_frame>1 week following treatment</time_frame>
    <description>Faecal C difficile PCR test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative CD toxin-test week 8</measure>
    <time_frame>8 weeks following treatment</time_frame>
    <description>Faecal C difficile PCR test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomy rate week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Date of colectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>EDQ5D-5L</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Clostridioides Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, FMT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin 125 x 4 for 10 days + 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label for screened, but not randomized patients with fulminant CDI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm exists for patients with fulminant CDI and for randomization to placebo may be considered unethical.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbiota transplantion (FMT)</intervention_name>
    <description>Single donor, fecal microbiota transplantion (FMT) from healthy human donors.</description>
    <arm_group_label>Open-label for screened, but not randomized patients with fulminant CDI</arm_group_label>
    <arm_group_label>Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Food coloring, water, glycerol</description>
    <arm_group_label>Vancomycin 125 x 4 for 10 days + 2 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. or 2. CDI (within a year) defined as: &gt; 3 bowel movements of Bristol 6-7 per day&#xD;
             and positive stool CD-test.&#xD;
&#xD;
          -  Age 18 years or higher.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Does not speak or understand the Danish language&#xD;
&#xD;
          -  Current antibiotic treatment other than vancomycin&#xD;
&#xD;
          -  Current treatment with potential interations with vancomycin&#xD;
&#xD;
          -  Allergy to vancomycin&#xD;
&#xD;
          -  Previous anaphylactic reactions due to food allergies&#xD;
&#xD;
          -  Continuous need for proton pump inhibitor&#xD;
&#xD;
          -  Documented gastroparesis&#xD;
&#xD;
          -  Fulminant CDI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian L Hvas, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon MD Baunwall, MD</last_name>
    <phone>+4578453800</phone>
    <email>simjor@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian L Hvas, PhD</last_name>
    <phone>+4578453800</phone>
    <email>christian.hvas@auh.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian L Hvas, PhD</last_name>
      <phone>+45 28351839</phone>
      <email>christian.hvas@auh.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Simon Mark D Baunwall, MD</last_name>
      <phone>+4578453800</phone>
      <email>simjor@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Hvas</investigator_full_name>
    <investigator_title>MD PhD Consultant</investigator_title>
  </responsible_party>
  <keyword>Fecal microbiota tranplantation, FMT, CDI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data may be obtained in a anonymous form compliant with the General Data Protection Regulation (GDPR)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

